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The effectiveness of a beta-blocker in patients with septic shock
Abstract
Background: The incidence of sepsis continues to increase. Septic shock is a major cause of mortality in the
United States and throughout the world. An adverse outcome of sepsis is cardiac dysfunction. Tachycardia
increases the workload on the heart, which increases the metabolic demands required. It is imperative to
identify new treatment options to help alleviate and manage the symptoms of sepsis. There are many potential
benefits of beta-blockers for acutely ill patients. This includes a decreased oxygen demand related to a
decreased heart rate (HR). This also results in reduced blood pressure and decreased workload of the heart.
Will the administration of beta-blockers be effective at controlling heart rate and mitigating the harmful effects
of beta-adrenergic receptor stimulation in patients with septic shock?
Methods: An extensive search was conducted using Medline-OVID, CINAHL, and Web of Science using the
keywords: beta-blocker and septic shock. The search was narrowed to only articles in English published within
the last two years. Articles that were relevant for data evaluating the use of beta-blockers in septic shock were
assessed for quality using the Grading of Recommendations, Assessment, Development, and Evaluation
(GRADE).
Results: Two studies met inclusion criteria and were included in this systematic review. A randomized clinical
trial with 336 participants demonstrated a decrease in 28-day mortality for septic shock patients receiving
esmolol infusion. It also showed that esmolol was effective at reducing heart rate and maintaining it within
desired levels while avoiding unwanted outcomes. A prospective observational pilot study evaluated 25 septic
shock patients in the ICU. The study demonstrated a controlled heart rate with a titrated infusion of esmolol.
It made evident a reduction in norepinephrine dosage, while maintaining microvascular blood flow and stroke
volume.
Conclusion: A titrated infusion of esmolol has been shown to reduce mortality in patients with septic shock.
These studies data support that the titrated administration of esmolol, a short acting beta-blocker, reduces HR
and maintain it within a target range of 80-94bpm. Secondary outcomes support its use in patients with septic
shock without significantly compromising the cardiac output of the patient and maintaining the
microcirculation of blood flow.
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Abstract 
 
Background: The incidence of sepsis continues to increase. Septic shock is a major 
cause of mortality in the United States and throughout the world.  An adverse outcome of 
sepsis is cardiac dysfunction. Tachycardia increases the workload on the heart, which 
increases the metabolic demands required. It is imperative to identify new treatment 
options to help alleviate and manage the symptoms of sepsis. There are many potential 
benefits of beta-blockers for acutely ill patients. This includes a decreased oxygen 
demand related to a decreased heart rate (HR). This also results in reduced blood pressure 
and decreased workload of the heart. Will the administration of beta-blockers be effective 
at controlling heart rate and mitigating the harmful effects of beta-adrenergic receptor 
stimulation in patients with septic shock? 
 
Methods:  An extensive search was conducted using Medline-OVID, CINAHL, and Web 
of Science using the keywords: beta-blocker and septic shock. The search was narrowed 
to only articles in English published within the last two years. Articles that were relevant 
for data evaluating the use of beta-blockers in septic shock were assessed for quality 
using the Grading of Recommendations, Assessment, Development, and Evaluation 
(GRADE). 
Results:  Two studies met inclusion criteria and were included in this systematic review. 
A randomized clinical trial with 336 participants demonstrated a decrease in 28-day 
mortality for septic shock patients receiving esmolol infusion. It also showed that esmolol 
was effective at reducing heart rate and maintaining it within desired levels while 
avoiding unwanted outcomes. A prospective observational pilot study evaluated 25 septic 
shock patients in the ICU. The study demonstrated a controlled heart rate with a titrated 
infusion of esmolol. It made evident a reduction in norepinephrine dosage, while 
maintaining microvascular blood flow and stroke volume.  
 
Conclusion:  A titrated infusion of esmolol has been shown to reduce mortality in 
patients with septic shock. These studies data support that the titrated administration of 
esmolol, a short acting beta-blocker, reduces HR and maintain it within a target range of 
80-94bpm. Secondary outcomes support its use in patients with septic shock without 
significantly compromising the cardiac output of the patient and maintaining the 
microcirculation of blood flow. 
 
Keywords:  beta-blocker, septic shock 
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The Effectiveness of Beta-Blocker Use in Patients with Septic Shock 
 
BACKGROUND 
 There has been a dramatic increase in the incidence of sepsis in recent years.1 In 
the 1970’s there was an estimated 164,000 cases of sepsis in the United States annually.2 
Recent estimates report more than 1.6 million cases of sepsis every year in the United 
States.2,3 There is a mortality rate greater than 200,000 per year for patients with septic 
shock.4 This increase in incidence among the population is linked to an increasing aging 
population, comorbidities, multidrug-resistant infections, and immunosuppression.5 
 Sepsis is a clinical syndrome that complicates severe infection. It results from a 
dysregulated inflammatory response to an infection. In sepsis we see a continuum of 
severity, which may result in systemic inflammatory response syndrome (SIRS) and 
multiple organ dysfunction syndrome (MODS). The body’s attempt to compensate for 
changes related to sepsis will be manifest in physiologic and clinical responses. Sepsis is 
often characterized by fever, tachycardia, tachypnea, altered mental status, and the 
cardinal signs of inflammation.  
 Shock is defined as a condition of severe impairment of tissue perfusion leading 
to cellular injury and dysfunction. There are several types of shock, but each results in 
hypo-perfusion, which leads to an inadequate delivery of oxygen to cells. With the less 
than required oxygen the cells start to dysfunction and release inflammatory mediators. 
These mediators set off a cascade of events that make perfusion even more inadequate 
due to changes occurring at the microvascular level. This often leads to a maldistribution 
of blood flow, which eventually leads to end organ damage and often death.4 With all 
types of shock the body tries to adapt to the hemodynamic changes placed on it.   
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 The progression of sepsis and septic shock is multifactorial. Septic shock is 
defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation. 
There is a significant decrease in systemic vascular resistance; to maintain perfusion there 
is often an increase in cardiac output. A detrimental side effect in patients with sepsis is 
cardiac dysfunction,6 increasing the rate of mortality to 70%.7 Tachycardia increases the 
workload on the heart, which increases the metabolic demands required. Sepsis creates a 
perfusion problem that leads to an imbalance between oxygen supply and demand.8 In 
sepsis the metabolic demands are high and this leads to a rapid depletion of adenosine 
triphosphate (ATP) and energy supply at the cellular level.9 Tissue hypoxia and 
inadequate perfusion are increased when the energy demand exceeds the actual supply.8 
 The production of cellular energy is decreased by damage to mitochondria, 
compromise of the circulatory system, and microcirculatory alterations.10  Adrenergic 
stimulation leads to increased protein and fat catabolism, hyperglycemia develops from 
gluconeogenesis and glycolysis, and all require increased energy demands.11 This higher 
increased expenditure contributes to organ dysfunction.11 To prevent irreversible organ 
damage and cell death, it is important to investigate and conduct studies to find improved 
ways to manage and treat septic shock quickly and effectively, thereby decreasing the 
mortality rate.  
 There are many potential benefits of beta-blockers for acutely ill patients. This 
includes a decreased oxygen demand related to a decreased heart rate (HR). This also 
results in reduced blood pressure and decreased workload of the heart.12 Esmolol is an 
effective beta-blocker that has a short half-life and has been used in CHF, CAD, and MIs 
with great success.13 What is the effectiveness of using a beta-blocker to control heart 
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rate and mitigate the harmful effects of beta-adrenergic receptor stimulation in patients 
with septic shock?  
METHODS 
 An extensive search was conducted using Medline-OVID, CINAHL, and Web of 
Science using the keywords: beta-blocker and septic shock. The search was narrowed to 
only articles in English published within the last two years. Articles that were relevant for 
data evaluating the use of beta-blockers in septic shock were assessed for quality using 
the Grading of Recommendations, Assessment, Development, and Evaluation 
(GRADE).14 
RESULTS 
  The initial search yielded 232 articles with many of the articles ranging back to 
the 1960’s. After evaluating relevant articles for high quality data and human studies, a 
total of two articles met inclusion criteria. These articles included a randomized control 
clinical trial15 and a pilot study.16 See Table 1 and 2. 
A Randomized Clinical Trial 
 This clinical trial15 was an open-label, randomized phase 2 study, to evaluate the 
use of esmolol to regulate heart rate and reduce the damaging effects of catecholamines 
while maintaining hemodynamic stability in patients with septic shock. The trial was 
performed in an ICU in a university hospital during the time frame of November, 2010 to 
July, 2012. There were 336 patients who were initially evaluated for the study. For 
various reasons 182 patients were excluded. A computer based random number generator 
was used to randomly assign the remaining 154 patients’ treatment with or without 
continuous infusion of esmolol. Seventy-seven patients were randomly allocated to each 
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of the treatment groups. The two groups were prognostically balanced, especially in 
regards to age, gender, body mass index (BMI), and preexisting conditions.15   
 Eligibility criteria consisted of the presence of septic shock requiring 
norepinephrine to maintain a mean arterial pressure (MAP) greater than or equal to 65 
mm Hg even after attempts to improve pressure with volume resuscitation. Additional 
inclusion criteria were a heart rate of 95 beats per minute (bpm) or greater, central venous 
pressure (CVP) ≥ 8 mm Hg, and pulmonary arterial occlusion pressure (PAOP) ≥ 12. 
Patients that were excluded from the study were those younger than 18 years of age, who 
were pregnant, with valvular heart disease, who had been given beta-blocker therapy 
prior to selection, or who had displayed severe cardiac dysfunction.15  
 The primary endpoint was to see if the administration of esmolol, an effective 
short acting beta-blocker, could decrease HR to less than 95 bpm and achieve a target HR 
between 80 and 90 bpm during their residence in the ICU. Secondary endpoints included 
28-day mortality, organ function, norepinephrine dosages, and oxygenation and 
cardiorespiratory indices. Acid-base balance, hemodynamics, and oxygenation were all 
monitored, evaluated, and assessed. This included radial and pulmonary artery 
catheterization, electrocardiography, labs, thermodilution technique to measure cardiac 
index, and the use of standard formulas to calculate ventricular stroke work, oxygen 
extraction, and oxygen delivery. Each variable was recorded at 24, 48,72, and 96 hours 
after eligibility and randomization were completed. For 28 days after starting the clinical 
trial, data was recorded for all unfavorable side effects including death.15  
 A two-sided t test was used to determine the sample size. It was found that 64 
patients would be needed for each group. To compensate for worst-case scenario, the 
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Wilcoxon Mann-Whitney test showed that the sample size needed to be increased to 75 
patients for each group.17 Baselines were compared with demographic data using a χ2 
test. AUCs (areas under the curve) calculations were used to avoid multiple comparisons. 
χ2 test was also used to compare 28-day mortality of the different groups. A multivariable 
Cox regression model was used to account for cofactors.15 
 The authors of the randomized clinical trial (RCT) concluded that esmolol was 
effective at reducing HR and maintaining it within desired levels while avoiding 
unwanted outcomes. The achieved HR was significantly lower during the intervention 
time frame in the esmolol group. In the RCT the 28 day mortality was decreased in the 
esmolol group with 38 deaths compared to 62 deaths in the control group.15  
 The authors identified five limitations of their study. Instead of an individualized 
HR for each patient a random set point was used. The use of esmolol titration required to 
control HR made the study so that it was non-blinded. The area in which the study was 
conducted had multidrug-resistant bacterial strains. It was difficult to determine if the 
non-cardiac actions of esmolol attributed to the witnessed decrease in mortality or if it 
was related to decreased HR. The authors were also unable to determine if the large 
difference between mortality of the two groups was due to confounding factors or a 
chance finding. Further clinical trials are needed to confirm the data and help resolve the 
limitations of the study.15  
Pilot Study 
 This prospective observational pilot study16 evaluated the effects of beta-blockers 
to control heart rate and decrease the negative effects of catecholamines in patients with 
septic shock. It was preformed in a multidisciplinary intensive care unit (ICU) at the 
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University of Rome and evaluated 25 septic shock patients in the ICU. The study used a 
case cross over design, which is an analytical epidemiological approach, in which the 
patients’ serves as their own control. It is used to investigate the effects of an intermittent 
exposure on the onset of acute outcomes.18 The study was conducted to evaluate the 
possible benefits of using a cardio selective beta-1 blocker, esmolol, to maintain heart 
rate within a target range and assess secondary benefits of beta-blocker therapy on 
hemodynamic stability.  
 Due to the patient’s condition, informed consent was obtained from the patients’ 
family. Selection criteria included patients who, even after sufficient fluid resuscitation, 
required norepinephrine to maintain a mean arterial pressure (MAP) equal to or greater 
than 65 mm Hg, and displayed a heart rate (HR) greater than 95 beats per minute (bpm).16 
These patients were administered a continuous infusion of esmolol, with the goal to 
achieve a HR between 80 and 94 bpm. All 25 selected candidates were ventilated and 
given midazolam and sufentanil for sedation. Patients were excluded for the following 
reasons, if they were younger than 18 years of age, were pregnant, had advanced valvular 
heart disease, or had significant cardiac dysfunction.16  
 Hemodynamic and microcirculation were assessed and monitored. 
Hemodynamics was monitored by pulmonary and radial artery catheterization. Heart rate 
was recorded by continuous telemetry. Blood gases were analyzed for each patient and 
stroke volume and oxygen indexes were calculated using standard formula. An optical 
probe was applied to the underside of the tongue to assess the microvascular blood flow. 
This was done using imaging from MicroScan that had five-fold magnification lens. The 
use of “De Backer Score” was used to calculate vessel density and the total number of 
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vessels lengths based on size (small, medium and large). Dividing these up into 
horizontal and vertical lines on the screen a score was calculated by dividing the number 
of lines by the length of the lines.19 This score was the microvascular flow index (MFI) 
that had a range of 0-3, with 3 being normal, 2 sluggish, 1 intermediate, and 0 absent. A 
formula multiplying the proportion of perfused vessels (PPVs) by vessel density was used 
to calculate perfused vessel density.16 
 Patients were given a titrated continuous infusion of esmolol beginning with a rate 
of 25mg/hr, maxing out at 2000mg/hr, to maintain a HR or 80-95 bpm. In addition to 
esmolol, the patients were provided standard treatment including fluid challenges, packed 
red blood cells (PRBCs) as needed, and administration of norepinephrine to maintain 
MAP. Each patient was reevaluated after 24 hours of esmolol infusion.16 
 A significant finding from the study showed no negative affect on microvascular 
blood flow, even after the reduction in HR from the administration of esmolol. The 
change in MFI following administration of esmolol was the primary endpoint for 
statistical analysis, with a correlation of 0.99, achieving 90% power was specified. Data 
was considered statistically significant for p value less than 0.05. After 24 hours of 
esmolol administration HR and cardiac index (CI) were significantly reduced. HR went 
from a baseline of 117 to 86 bpm. Cardiac index decreased from a baseline of 4.0 to 3.1. 
The amount of norepinephrine needed was also greatly decreased from 0.53 µg/kg/min to 
0.41 µg/kg/min. There was improvement in acid-base homeostasis and oxygenation. The 
consumption index and the demand for oxygen delivery decreased. The MFI data showed 
significant increase from 2.8 to 3.0.16 
 This was the first clinical study to assess the effects of esmolol to reduce and 
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maintain heart rate in patients with septic shock. To ensure the safety of the patient a 
case-cross over design was used, therefore the patient acted as the control. No control 
group was present in the study and therefore the findings might be related to the patient’s 
own improvement, rather than the benefits of a decreased HR from the administration of 
a beta-blocker. The sample size was small, but the data does support a positive outcome 
from esmolol.16 
DISCUSSION 
 In the United States the incidence of severe sepsis and septic shock is greater than 
1.6 million per year2,3 with a mortality of more than 200 000 per year.4 The incidence 
continues to rise as patients now live longer and present with more comorbid conditions 
that are being managed with greater efficiency by modern medicine. In view of the 
epidemiology, it is imperative to continue to investigate additional options to help treat 
septic shock and decrease mortality.  
 Esmolol provides a reasonable approach to treat patients’ with septic shock. In the 
clinical trial15 data illustrated that esmolol was effective in decreasing HR while 
maintaining MAP (see Table 2). In addition, secondary outcomes were identified and 
determined to be beneficial. The group who received esmolol demonstrated a decrease in 
the dosage of norepinephrine administration to maintain MAP.15,16 The concern with the 
administration of esmolol was that decreased HR would decrease cardiac output, which 
would have an adverse effect on MAP.8 This was shown not to be the case. The findings 
suggest that a decreased HR allowed for greater ventricular filling during diastole.15 This 
resulted in notable improvement in stroke volume and left ventricular stroke work indices 
in the esmolol group.15 The need for IV fluid administration was also decreased in the 
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esmolol group.15,16  
 Statistical analysis of the data from the clinical study also showed an increase in 
pH and a decrease in lactate concentration,15 which indicates a decrease in aerobic 
metabolism. Kidney function was also shown to have a positive improvement in the 
esmolol group.15 Glomerular filtration rate (GFR) for those being treated with esmolol 
was 14ml/min/1.73m2 compared to the control group with a GFR of 214ml/min/1.73m2. 
The partial pressure of O2 to inspired oxygen fraction ratio also increased for the esmolol 
group.15 The esmolol group had myocardial injury bio-markers, troponin and creatine, 
that were lower.15  
 A significant outcome in the study was improved survival rate in the esmolol 
group. The 28-day mortality was almost double for the control group when compared to 
those receiving esmolol (49.4% vs 80.5%).15  
 While both studies15,16 demonstrated that a titrated infusion of esmolol was 
effective in reducing HR and maintaining it in a target range, without adversely affecting 
MAP, stroke volume, lactate levels, or norepinephrine requirement; both studies had 
limitations. In the clinical trial15 it would be difficult to use a placebo in place of esmolol 
to regulate heart rate. Many patients were excluded from the study because they did not 
have tachycardia. As with all drugs, the administration of beta-blockers, does not happen 
without a myriad of possible adverse reactions.20 There is still debate about whether 
treating tachycardia in septic shock is recommended.8,15 Tachycardia is a main 
mechanism to overcome decreased cardiac output in the early phase of septic shock.21 
The ideal heart rate and timeframe are still undetermined. A major limitation of the pilot 
study was the small sample size. Both studies had a high risk for selection bias because 
 - 16 -  
there were conducted in only one University.  
CONCLUSION 
  The studies15,16 data supports the titrated administration of esmolol, a short acting 
beta-blocker, to reduce HR and maintain it within a target range of 80-94bpm. Secondary 
outcomes support its use in patients with septic shock without significantly 
compromising the cardiac output of the patient and maintaining the microcirculation of 
blood flow.15,16 Notable improvement was seen in stroke volume, MAP, decreased 
dosage of norepinephrine, and less deleterious effects to organ function.15 The evidence 
for the use of esmolol in septic-shock patients is positive and data demonstrated an 
increased survival rate. There was a 30% decrease in 28 day mortality in the RCT.15 The 
overall combined quality of the studies reviewed is low based on the GRADE criteria. 
More studies need to be conducted to see if the use of a beta-blocker earlier in the 
treatment of patients’ with sepsis is beneficial. Further research is also required to 
investigate the effects of beta-blockers on clinical outcomes.   
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TABLE 1 GRADE evidence profile: Esmolol use in patients with septic shock 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aNo blinding in the RCT15 and both studies15,16 contained a high risk for selection bias because it was conducted in just one University. 
bSmall sample size in the observational pilot study16 
cFailure to capture individualized HR in the RCT15 
 
Table 2 Summary of Results 
 
Quality Assessment  
Importance  Downgrade Criteria 
Quality No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Decreased HR (target range 80-94bpm)  
2 
 
1 RCT 
1 Observational 
pilot 
 Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb,c 
No serious 
inconsistencies 
No bias 
likely Low Critical 
Mortality (28 day)  
2 
1 RCT 
1 Observational 
pilot 
 No 
Serious 
limitations 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely Moderate Critical 
Mean arterial pressure (MAP)  
2 
1 RCT 
1 Observational 
pilot 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely Low Critical 
Norepinephrine dosage  
2 
1 RCT 
1 Observational 
pilot 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely Low Critical 
Stroke volume  
2 
1 RCT 
1 Observational 
pilot 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely Low Critical 
Study Randomized Controlled 
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Observational Pilot Study16 
Time Interval Baseline 24 hours Baseline 24 hours 
 
Heart 
Rate (/min) 
Treatment group 114 84 117 86  
Control 
group 
114 112 N/A N/A 
 
28-day  
Mortality 
Treatment group  38/77= 49.4% N/A Not evaluated Not evaluated 
Control 
group 
62/77= 80.5% N/A N/A N/A 
 
Nor-epinephrine 
dosage 
(µg/kg/min) 
Treatment group 0.4 0.25 0.53 0.41 
Control 
group 
0.4 0.39 N/A N/A 
 
Mean 
Arterial  
Pressure (mm 
Hg) 
Treatment group 73 72 71 72 
Control 
group 
72 72 N/A N/A 
 
Stroke 
Volume 
(mL/beat2/m2) 
Treatment group 36 40 34 40 
Control 
group 
34 34.3 N/A N/A 
